FDA Requests More Information From Baxter And Halo

Posted on April 16, 2012 at 14:32 PM EDT

The Food and Drug Administration requested additional information in order to complete its review of Baxter International Inc.'s (NYSE: BAX) and Halozyme Therapeutics Inc.'s (Nasdaq: HALO) HyQ Biologics License Application. Shares of Baxter plummeted $3.95 to $54.08 while Halozyme stock plunged $2.53 to $8.74.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates